Ikarian Capital, LLC I Mab Transaction History

Ikarian Capital, LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$57.18 - $84.43 $2.63 Million - $3.89 Million	-46,066 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$47.86 - $83.95 $9.76 Million - $17.1 Million	-203,934 Reduced 81.57%	46,066 $3.87 Million
Q1 2021 May 17, 2021	BUY	$44.38 - $63.97 $4.44 Million - $6.4 Million	100,000 Added 66.67%	250,000 $12.1 Million
Q3 2020 Nov 16, 2020	BUY	$27.46 - $47.03 $4.12 Million - $7.05 Million	150,000 New	150,000 $7.05 Million

15.5M

56.4K

5.8K

Ticker IMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,098,800
Market Cap $87.3M
Description
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Ikarian Capital, LLC with notifications on news.